Related Experiment Videos
A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
P M Deckert1, C Renner, L S Cohen
1Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany. deckert@medizin.fu-berlin.de
British Journal of Cancer
|March 20, 2003
Abstract:
A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.